Real-world data shows strong symptom relief and patient satisfaction with Teva’s Austedo XR

Teva Pharmaceuticals announced new real-world survey findings demonstrating meaningful symptom improvement and strong treatment satisfaction among patients with tardive dyskinesia (TD) taking AUSTEDO XR (deutetrabenazine) extended-release tablets. The data were presented at the 2025 Psych Congress Annual Meeting, held September 17–21 in San Diego, California.

“The reality of tardive dyskinesia goes beyond clinical symptoms—it affects people’s daily lives, their confidence, and their ability to connect socially,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “At Teva, we are deeply committed to understanding the lived experiences of patients and ensuring that treatments like AUSTEDO XR not only manage symptoms but also restore a sense of freedom and well-being.”

The noninterventional, prospective, cross-sectional survey included patients with varying treatment backgrounds, including those who were treatment-naïve and those with prior valbenazine use. Across both groups, patients consistently reported reduced motor symptoms, a positive experience with dose flexibility, and a high level of satisfaction with AUSTEDO XR.

These findings underscore the meaningful role AUSTEDO XR can play in the treatment of tardive dyskinesia, offering patients not only clinical improvement but also measurable benefits in social and emotional aspects of daily life.